Sirona Biochem

Investor Insight

Sirona Biochem is on track to commercialize its proprietary anti-aging product, increasing shareholder value and enhancing profitability.

Overview

Sirona Biochem (TSXV:SBM,FSE:ZSB,US OTC:SRBCF) is a biotechnology company with an innovative platform for developing safer, more effective cosmetic and therapeutic active ingredients. Sirona Biochem’s strategy involves bringing innovative patented compounds to market while also engaging in partnerships to license or sell them to prominent global enterprises. In exchange, receiving income generating sales, front-end fees, milestone payments, and ongoing royalties.

Sirona’s technology is based on proprietary carbohydrate chemistry developed by the company’s wholly-owned French subsidiary research and development (R&D) laboratory TFChem. This carbohydrate chemistry can improve the safety and efficacy of carbohydrate-based molecules, which have broad application potential for the development of therapeutics and cosmeceuticals. Examples of commercially available carbohydrate-based drugs include viral neuraminidase inhibitor Tamiflu, and Johnson & Johnson’s (NYSE:JNJ) SGLT2 inhibitor Invokana™.

The company has an exclusive global licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE:ABBV), to commercialize topical skin care treatments for dyschromia based on Sirona’s patents for TFC-1067 and related family of compounds. TFC-1067 is a very potent but safe dark spot remover and a breakthrough in the industry.

Sirona’s commercial launch of a serum containing our GlycoProteMim™ in 2025 is on track. The company’s Paris-based cosmetic branding expert has developed a compelling strategy to position this product as a premium offering in the anti-aging market highlighting GlycoProteMim's™ rejuvenating properties. GlycoProteMim™ serum will provide consumers with aging skin a breakthrough solution, delivering unmatched benefits without any observed adverse effects.

Sirona is led by a highly experienced team of biotechnology professionals. The company’s chief scientific officer Dr. Géraldine Deliencourt-Godefroy is an award-winning synthetic chemist and the founder of the French biotechnology company TFChem. Her scientific research in carbohydrate chemistry has led to the discovery of new drug families and the development of drug candidates for diabetes and obesity, cosmetic ingredients and biological adjuvants. She is the recipient of the acclaimed Francinov Research and Innovation Medal, the French Ministry of Research Award and the French Senate Award.

Technology Platform

Sirona’s technology platform is based on proprietary carbohydrate chemistry. Carbohydrate molecules play a central role in cell-to-cell communication and can interact with proteins, hormones, viruses, toxins and bacteria. In this way, carbohydrates perform a variety of essential biological functions in the human body, making them valuable components for the development of therapeutics and cosmeceuticals.

While they have broad application potential, carbohydrates are extremely challenging to develop due to their inherent instability. Using chemistry techniques originally developed by TFChem, Sirona has overcome the challenge of stabilizing carbohydrates to develop safer, more effective cosmetic and therapeutic active ingredients.

Sirona is exploring multiple commercial opportunities and partnerships for its carbohydrate technology platform and currently has two streams of product line: cosmetics and therapeutics.

Company Highlights

• Proven technology platform based on proprietary carbohydrate chemistry leading to a pipeline of products across a broad range of applications in cosmetics and pharmaceuticals all based on 20 years of research and development.
• Signed global exclusive licensing deal with Allergan Aesthetics, an AbbVie [NYSE: ABBV] company, for TFC-1067 and related family of compounds for the treatment of dyscromiadyschromia.
• Under the license agreement, Sirona will receive payments on achievement of milestones and royalties on product sales. Seventeen years duration for TFC-1067 patents.
• Strong worldwide IP portfolio, including North America, European Union and Asia.
• Developing disruptive solutions for anti-aging (US$12.5 billion), dyschromia(US$7.5 billion), and cellulite treatment (US$ 1.4 billion).
• Preparing for a planned commercial launch of anti-aging anti-wrinkle skincare product first quarter 2025 containing Sirona’s GlycoProteMim™ ingredient.
• State-of-the-art, laboratory in Paris France with award winning scientific team.

Key Business Segments

TFC-1067

June 13 2022 Sirona announced it has entered into a global licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE:ABBV), pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based Sirona’s TFC-1067 and related family of compounds. Work is underway to bring product(s) containing TFC-1067 to commercial sales. Sirona will receive payments on the achievement of milestones and royalties on product sales.

GlycoProteMim™

GlycoProteMim™ (TFC-1326) is a revolutionary compound that offers remarkable anti-aging results and stands out as a beacon of innovation and safety. Unlike traditional alternatives such as toxins, dermal fillers, and retinoids, GlycoProteMim™ offers a unique solution that is safe and effective in reversing skin aging.

GlycoProteMim™ heightens cellular response to reactive oxygen species (ROS) and boosts SOD2. The compound also enhances hyaluronic acid synthesis and increases fibroblast proliferation, fortifying the collagen network.

Product Highlights:

• Safe for All Skin Types: GlycoProteMim™ is designed for all skin types. It has been proven to be tolerated by 100 percent of participants in clinical trials.
• Natural Progression, Not Injection: GlycoProteMim™ is a topical application and does not require invasive injections.
• Anti-Aging Efficacy: The product is loaded with powerful anti-inflammatory effects. It reverses aging and repairs skin, offering a comprehensive and permanent solution.

Multifaceted Benefits: GlycoProteMim™ outshines alternatives by helping improve skin laxity and quality and providing UV protection while enhancing the skin barrier. Retinoids, while effective, come with challenges like skin irritation and a lengthy onset period, making GlycoProteMim™ a more versatile and user-friendly alternative.

Sirona’s subsidiary, TFChem, has successfully received formulations for its eagerly awaited GlycoProteMim™ based anti-aging serum from its formulation partner, Global Beauty Consulting. The formulation intends to define the brand and lay the foundation for a broader range of products. This formulation will undergo standard safety evaluations and be used in the upcoming clinical trial. Sirona plans to launch the product in early 2025, ensuring compliance with regulatory standards in the European, US, and Canadian markets.

Cellulite Treatment, Wound care, and Keloid Treatments

Sirona’s scientists have identified new molecules underscoring its commitment to comprehensive skincare solutions developed by TFChem for the treatments of cellulite, wound care and keloids. Research plans have been developed and will be implemented when sufficient resources become available. There is a massive unmet need for effective treatments in these areas spanning both cosmetics and therapeutic markets.

Melasma Therapeutics

Sirona has retained the rights to commercialize TFC-1067 and related compound TFC-1394 as a therapeutic for the treatment of melasma. The potential exists to produce an effective therapeutic agent free of hydroquinone.

Management Team

Dr. Howard J. Verrico - CEO and Chairman of the Board

Dr. Verrico obtained his medical degree from the University of Toronto in 1985 and has been a member of the College of Physicians and Surgeons of British Columbia since July 1986. Dr. Verrico has extensive experience as a venture capitalist in the junior capital markets. He has acted as a venture capitalist for over 30 years, funding numerous start-ups and early-stage companies both in the private and public marketplace. He is the founder of Sirona Biochem building the company by investing his personal funds starting in 2006, He has accumulated his large share position through personal share purchases. He currently is solely focused on the success and growth of SIRONA Biochem as it enters a stage of rapid growth.

Géraldine Deliencourt-Godefroy - Chief Scientific Officer

Dr. Géraldine Deliencourt-Godefroy is an award-winning synthetic chemist and the founder of French-based biotechnology company TFChem. Since the acquisition of TFChem by Sirona Biochem in March 2011, Dr. Deliencourt-Godefroy has assumed the role of Chief Scientific Officer. Her scientific research in carbohydrate chemistry has led to the discovery of new drug families and the development of drug candidates for diabetes and obesity, cosmetic ingredients and biological adjuvants. Previous to founding TFChem, Dr. Deliencourt-Godefroy was a scientific leader at INSA (National Institute of Applied Sciences) in Rouen, France, where she developed a new technology on stabilized carbohydrates. Previous roles also include a post-doctoral position at the University College London and doctoral research at the Research Institute of Fine Organic Chemistry in Rouen, France. Dr. Deliencourt-Godefroy received a PhD and Masters in Organic Chemistry as well as her business degree from the University of France. She is the author of several publications and patents and is also the recipient of the acclaimed Francinov Research and Innovation Medal, the French Ministry of Research Award and the French Senate Award.

Christopher Hopton - Chief Financial Officer

Christopher Hopton brings 28 years of financial management and operations expertise to the company. His extensive background includes financial planning, accounting policy, and business process improvement. As a business investment and finance consultant, he has worked with multiple public and private companies. Noteworthy roles include serving as chief financial officer at Central Resources and Rio Silver, as well as a division controller at Canadian Airlines, where he managed a $200 million annual operating budget. He played a key role in the restructuring of 360 Networks, leading to its acquisition by Bell Canada. Hopton holds a Bachelor of Business Administration from Simon Fraser University and is a Certified Professional Accountant.